Welcome to LookChem.com Sign In|Join Free

CAS

  • or

133982-66-8

Post Buying Request

133982-66-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

133982-66-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 133982-66-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,9,8 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 133982-66:
(8*1)+(7*3)+(6*3)+(5*9)+(4*8)+(3*2)+(2*6)+(1*6)=148
148 % 10 = 8
So 133982-66-8 is a valid CAS Registry Number.
InChI:InChI=1/C18H20F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13H,1-2,7-11H2

133982-66-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-fluorophenyl)-4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]butan-1-one

1.2 Other means of identification

Product number -
Other names 1-Butanone,1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:133982-66-8 SDS

133982-66-8Downstream Products

133982-66-8Relevant articles and documents

Synthesis and Biological Characterization of α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and Analogues as Potential Atypical Antipsychotic Agents

Yevich, Joseph P.,New, James S.,Lobeck, Walter G.,Dextraze, Pierre,Brenstein, Edith,et al.

, p. 4516 - 4525 (2007/10/02)

A series of 1-(pyrimidin-2-yl)piperazine derivatives were prepared and evaluated in receptor binding assays and in in vivo behavioral paradigms as potential atypical antipsychotic agents.Compound 16 (BMS 181100 (formerly BMY 14802)) emerged as the lead compound from within the series on the basis of its good activity and duration of action in the inhibition of both conditioned avoidance responding and apomorphine-induced stereotopy in the rat.Compound 16 not only failed to induce catalepsy in the rat but was quite effective in reversing the cataleptic effect of neurolepti c agents, thus indicating a low propensity for causing extrapyramidal side effects.In comparison to reference antipsychotic agents, 16 appeared to be less sedating and was relatively weaker in causing muscle incoordination.The compound was essentially inactive in binding to dopamine D2 receptors and its chronic administration to rats did not result in dopamine receptor supersensitivity.It exhibited modest to weak affinity for 5-HT1A and α1 receptors but was found to be a fairly potent ligand for ? binding sites (IC50 vs (+)--3-PPP = 112 nM).Although the resolved enantiomers of racemic 16 did not show dramatic differences from racemate or from each other in most tests, the R(+) enantiomer was up to 11-fold more potent than its antipode in binding to ? sites.Several studies have indicated that 16 may be a limbic-selective agent which may modulate dopaminergic activity by an indirect mechanism.The compound has been selected for clinical evaluation in the treatment of psychosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 133982-66-8